Perioperative chemotherapy for muscle-invasive bladder cancer

Authors

  • Peter Black Department of Urologic Sciences, UBC, Vancouver, BC
  • Alan So Department of Urologic Sciences, UBC, Vancouver, BC

DOI:

https://doi.org/10.5489/cuaj.1202

Abstract

Considerable debate exists concerning the combined use of systemic
chemotherapy and radical surgery for muscle-invasive bladder
cancer. While there is evidence for a survival benefit after
neoadjuvant chemotherapy, the benefit is modest and the potential
toxicity and delay of time to surgery prior to cystectomy appears
to be deterring many surgeons from its administration. The evidence
for adjuvant chemotherapy, on the other hand, is less compelling
and substantial. Furthermore, the role of adjuvant compared
to salvage chemotherapy requires further investigation.
Similarly, research continues on identifying molecular and clinical
markers to best stratify patients for optimal perioperative therapy.
In this article, the evidence for radical cystectomy and
chemotherapy, given either in a neoadjuvant or adjuvant setting,
will be reviewed.

Downloads

Download data is not yet available.

Author Biographies

Peter Black, Department of Urologic Sciences, UBC, Vancouver, BC

Alan So, Department of Urologic Sciences, UBC, Vancouver, BC

Downloads

How to Cite

Black, P., & So, A. (2013). Perioperative chemotherapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 3(6-S4), S223-S227. https://doi.org/10.5489/cuaj.1202